Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
Perez, Matthew C, Zager, Jonathan S, Amatruda, Thomas, Conry, Robert, Ariyan, Charlotte, Desai, Anupam, Kirkwood, John M, Treichel, Sheryl, Cohan, David, Raskin, Leon
Published in Melanoma management (01.06.2019)
Published in Melanoma management (01.06.2019)
Get full text
Journal Article
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
Long, Georgina, Dummer, Reinhard, Johnson, Douglas, Michielin, Olivier, Martin-Algarra, Salvador, Treichel, Sheryl, Chan, Edward, Diede, Scott, Ribas, Antoni
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Chesney, Jason A, Ribas, Antoni, Long, Georgina V, Kirkwood, John M, Dummer, Reinhard, Puzanov, Igor, Hoeller, Christoph, Gajewski, Thomas F, Gutzmer, Ralf, Rutkowski, Piotr, Demidov, Lev, Arenberger, Petr, Shin, Sang Joon, Ferrucci, Pier Francesco, Haydon, Andrew, Hyngstrom, John, van Thienen, Johannes V, Haferkamp, Sebastian, Guilera, Josep Malvehy, Rapoport, Bernardo Leon, VanderWalde, Ari, Diede, Scott J, Anderson, James R, Treichel, Sheryl, Chan, Edward L, Bhatta, Sumita, Gansert, Jennifer, Hodi, Frank Stephen, Gogas, Helen
Published in Journal of clinical oncology (20.01.2023)
Published in Journal of clinical oncology (20.01.2023)
Get full text
Journal Article
One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL)
Dummer, Reinhard, Gyorki, David E., Hyngstrom, John Robert, Berger, Adam C., Conry, Robert Martin, Demidov, Lev V., Sharma, Anjali, Treichel, Sheryl, Faries, Mark B., Ross, Merrick I.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Checkpoint inhibitor (CPI) experienced patients (pts) from COSMUS-1: A clinical observational study of talimogene laherparepvec (T-VEC) in United States practice
Perez, Matthew, Amatruda, Thomas, Conry, Robert Martin, Ariyan, Charlotte Eielson, Desai, Anupam M., Kirkwood, John M., Treichel, Sheryl, Ismail, Rubina, Raskin, Leon
Published in Journal of clinical oncology (10.03.2019)
Published in Journal of clinical oncology (10.03.2019)
Get full text
Journal Article
Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)
Andtbacka, Robert Hans Ingemar, Dummer, Reinhard, Gyorki, David E., Berger, Adam C., Conry, Robert Martin, Demidov, Lev V., Chan, Edward, Treichel, Sheryl, Faries, Mark B., Ross, Merrick I.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232)
Harrington, Kevin J., Kong, Anthony Hee, Mach, Nicolas, Rordorf, Tamara, Corral Jaime, Jesus, Espeli, Vittoria, Treichel, Sheryl, Gumuscu, Burak, Kim, Jenny J., Chesney, Jason Alan
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article